{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:34:12Z","timestamp":1759412052837,"version":"3.37.3"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2020-2021"],"award-info":[{"award-number":["2020-2021"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>mRNA SARS-CoV-2 vaccines are administered to 2 million individuals per day in the United States under US Food and Drug Administration emergency use authorization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Observational cohort study of hospital employees who received their first SARS-CoV-2 mRNA vaccination between 14 December 2020 and 8 January 2021, including employees who reported onset of an injection site reaction \u226548 hours after administration of their first or second dose to an employee hotline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirteen female employees who received the mRNA-1273 vaccine (Moderna) during the first 3 weeks of the SARS-CoV-2 vaccine rollout at San Francisco General Hospital reported a pruritic rash at the injection site appearing 3 -9 days after receipt of their initial dose. Five had milder or similar reactions with earlier onset after the second dose. One additional female employee reported this delayed reaction only after the second dose. None reported serious adverse events or had symptoms severe enough to seek medical attention. These cases represented 1.1% of the 1275 female employees who received their first mRNA-1273 dose and 2.0% of the 557 who were aged 31 -45 years during this initial vaccine rollout. None of 675 males who initiated mRNA-1273 or 3612 employees of any sex who initiated BNT162b (Pfizer) vaccination during this period reported delayed-onset reactions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results suggest that delayed-onset, injection site pruritic rashes after mRNA-1273 SARS-CoV-2 vaccine administration, lasting up to 1 week, occur commonly in females, do not lead to serious sequela, and should not deter receipt of the second vaccine dose.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab518","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T20:11:58Z","timestamp":1622751118000},"page":"591-596","source":"Crossref","is-referenced-by-count":12,"title":["Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees"],"prefix":"10.1093","volume":"74","author":[{"given":"Mark A","family":"Jacobson","sequence":"first","affiliation":[{"name":"Division of Occupational Medicine, University of California\u2013San Francisco School of Medicine , San Francisco, California ,","place":["USA"]},{"name":"Division of HIV, Infectious Diseases, and Global Medicine, University of California\u2013San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Zakaria","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California\u2013San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaw","family":"Maung","sequence":"additional","affiliation":[{"name":"Division of Occupational Medicine, University of California\u2013San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Public Health, San Francisco Department of Public Health , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy H","family":"McCalmont","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California\u2013San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlys","family":"Fassett","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California\u2013San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Amerson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California\u2013San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"year":"2021","key":"2024111411414636200_CIT0001"},{"year":"2020","author":"Our World in Data. Vaccines and Related Biological Products Advisory Committee","key":"2024111411414636200_CIT0002"},{"key":"2024111411414636200_CIT0003","article-title":"Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2 [published online ahead of print, 2021 Mar 3]","author":"Blumenthal","year":"2021","journal-title":"N Engl J Med"},{"key":"2024111411414636200_CIT0004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jdcr.2021.02.014","article-title":"\u201cCOVID arm\u201d: a reaction to the Moderna vaccine","volume":"10","author":"Wei","year":"2021","journal-title":"JAAD Case Rep"},{"year":"2011","author":"Howden","key":"2024111411414636200_CIT0005"},{"key":"2024111411414636200_CIT0006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"author":"Kaiser Family Foundation.","key":"2024111411414636200_CIT0007"},{"key":"2024111411414636200_CIT0008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024111411414636200_CIT0009","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1111\/bcp.14112","article-title":"Immune-mediated adverse reactions to vaccines","volume":"85","author":"Stone","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2024111411414636200_CIT0010","first-page":"S2213-2198(20)31411","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","author":"Banerji","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024111411414636200_CIT0011","first-page":"S0190-9622(21)00658","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024111411414636200_CIT0012","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study","volume":"85","author":"de Vries","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2024111411414636200_CIT0013","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am J Clin Dermatol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab518\/39068704\/ciab518.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/4\/591\/42672922\/ciab518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/4\/591\/42672922\/ciab518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:37:32Z","timestamp":1731587852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/74\/4\/591\/6291929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,4]]},"published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab518","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2022,2,15]]},"published":{"date-parts":[[2021,6,4]]}}}